Diagnostic system strengthening for drug resistant tuberculosis in Nigeria: impact and challenges.
Identifieur interne : 004637 ( Ncbi/Merge ); précédent : 004636; suivant : 004638Diagnostic system strengthening for drug resistant tuberculosis in Nigeria: impact and challenges.
Auteurs : Gambo Aliyu [États-Unis] ; Nicholas Ezati [Nigeria] ; Mosunmola Iwakun [Nigeria] ; Sam Peters [Nigeria] ; Alash'Le Abimiku [États-Unis]Source :
- African journal of laboratory medicine [ 2225-2002 ] ; 2017.
Abstract
The increasing prevalence of drug-resistant tuberculosis and the threat of extensively-drug-resistant tuberculosis in HIV hotspots have made the detection and treatment of drug-resistant tuberculosis in the sub-Saharan Africa setting a global public health priority.
DOI: 10.4102/ajlm.v6i2.502
PubMed: 28879163
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000E48
- to stream PubMed, to step Curation: 000E48
- to stream PubMed, to step Checkpoint: 000E48
Links to Exploration step
pubmed:28879163Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Diagnostic system strengthening for drug resistant tuberculosis in Nigeria: impact and challenges.</title><author><name sortKey="Aliyu, Gambo" sort="Aliyu, Gambo" uniqKey="Aliyu G" first="Gambo" last="Aliyu">Gambo Aliyu</name><affiliation wicri:level="2"><nlm:affiliation>Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Ezati, Nicholas" sort="Ezati, Nicholas" uniqKey="Ezati N" first="Nicholas" last="Ezati">Nicholas Ezati</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Human Virology, Abuja, FCT, Nigeria.</nlm:affiliation><country xml:lang="fr">Nigeria</country><wicri:regionArea>Institute of Human Virology, Abuja, FCT</wicri:regionArea><wicri:noRegion>FCT</wicri:noRegion></affiliation></author><author><name sortKey="Iwakun, Mosunmola" sort="Iwakun, Mosunmola" uniqKey="Iwakun M" first="Mosunmola" last="Iwakun">Mosunmola Iwakun</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Human Virology, Abuja, FCT, Nigeria.</nlm:affiliation><country xml:lang="fr">Nigeria</country><wicri:regionArea>Institute of Human Virology, Abuja, FCT</wicri:regionArea><wicri:noRegion>FCT</wicri:noRegion></affiliation></author><author><name sortKey="Peters, Sam" sort="Peters, Sam" uniqKey="Peters S" first="Sam" last="Peters">Sam Peters</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Human Virology, Abuja, FCT, Nigeria.</nlm:affiliation><country xml:lang="fr">Nigeria</country><wicri:regionArea>Institute of Human Virology, Abuja, FCT</wicri:regionArea><wicri:noRegion>FCT</wicri:noRegion></affiliation></author><author><name sortKey="Abimiku, Alash Le" sort="Abimiku, Alash Le" uniqKey="Abimiku A" first="Alash'Le" last="Abimiku">Alash'Le Abimiku</name><affiliation wicri:level="2"><nlm:affiliation>Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28879163</idno><idno type="pmid">28879163</idno><idno type="doi">10.4102/ajlm.v6i2.502</idno><idno type="wicri:Area/PubMed/Corpus">000E48</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000E48</idno><idno type="wicri:Area/PubMed/Curation">000E48</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000E48</idno><idno type="wicri:Area/PubMed/Checkpoint">000E48</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000E48</idno><idno type="wicri:Area/Ncbi/Merge">004637</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Diagnostic system strengthening for drug resistant tuberculosis in Nigeria: impact and challenges.</title><author><name sortKey="Aliyu, Gambo" sort="Aliyu, Gambo" uniqKey="Aliyu G" first="Gambo" last="Aliyu">Gambo Aliyu</name><affiliation wicri:level="2"><nlm:affiliation>Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Ezati, Nicholas" sort="Ezati, Nicholas" uniqKey="Ezati N" first="Nicholas" last="Ezati">Nicholas Ezati</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Human Virology, Abuja, FCT, Nigeria.</nlm:affiliation><country xml:lang="fr">Nigeria</country><wicri:regionArea>Institute of Human Virology, Abuja, FCT</wicri:regionArea><wicri:noRegion>FCT</wicri:noRegion></affiliation></author><author><name sortKey="Iwakun, Mosunmola" sort="Iwakun, Mosunmola" uniqKey="Iwakun M" first="Mosunmola" last="Iwakun">Mosunmola Iwakun</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Human Virology, Abuja, FCT, Nigeria.</nlm:affiliation><country xml:lang="fr">Nigeria</country><wicri:regionArea>Institute of Human Virology, Abuja, FCT</wicri:regionArea><wicri:noRegion>FCT</wicri:noRegion></affiliation></author><author><name sortKey="Peters, Sam" sort="Peters, Sam" uniqKey="Peters S" first="Sam" last="Peters">Sam Peters</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Human Virology, Abuja, FCT, Nigeria.</nlm:affiliation><country xml:lang="fr">Nigeria</country><wicri:regionArea>Institute of Human Virology, Abuja, FCT</wicri:regionArea><wicri:noRegion>FCT</wicri:noRegion></affiliation></author><author><name sortKey="Abimiku, Alash Le" sort="Abimiku, Alash Le" uniqKey="Abimiku A" first="Alash'Le" last="Abimiku">Alash'Le Abimiku</name><affiliation wicri:level="2"><nlm:affiliation>Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author></analytic><series><title level="j">African journal of laboratory medicine</title><idno type="ISSN">2225-2002</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The increasing prevalence of drug-resistant tuberculosis and the threat of extensively-drug-resistant tuberculosis in HIV hotspots have made the detection and treatment of drug-resistant tuberculosis in the sub-Saharan Africa setting a global public health priority.</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">28879163</PMID><DateCreated><Year>2017</Year><Month>09</Month><Day>07</Day></DateCreated><DateRevised><Year>2017</Year><Month>09</Month><Day>10</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2225-2002</ISSN><JournalIssue CitedMedium="Print"><Volume>6</Volume><Issue>2</Issue><PubDate><Year>2017</Year></PubDate></JournalIssue><Title>African journal of laboratory medicine</Title><ISOAbbreviation>Afr J Lab Med</ISOAbbreviation></Journal><ArticleTitle>Diagnostic system strengthening for drug resistant tuberculosis in Nigeria: impact and challenges.</ArticleTitle><Pagination><MedlinePgn>502</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4102/ajlm.v6i2.502</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The increasing prevalence of drug-resistant tuberculosis and the threat of extensively-drug-resistant tuberculosis in HIV hotspots have made the detection and treatment of drug-resistant tuberculosis in the sub-Saharan Africa setting a global public health priority.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We sought to examine the impact and challenges of tuberculosis diagnostic capacity development for the detection of drug-resistant tuberculosis and bio-surveillance using a modular biosafety level 3 (BSL-3) laboratory in Nigeria.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">In 2010, the United States President's Emergency Plan for AIDS Relief (PEPFAR) programme, through the Institute of Human Virology at the University of Maryland in Baltimore, Maryland, United States, deployed a modular, BSL-3 laboratory to support the national tuberculosis programme in drug-resistant tuberculosis detection and bio-surveillance for effective tuberculosis prevention and control.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">From 2010 until present, sputum samples from 11 606 suspected cases in 33 states were screened for drug-resistant tuberculosis. Of those, 1500 (12.9%) had mono-resistant tuberculosis strains, and 459 (4.0%) cases had multidrug-resistant tuberculosis. Over the last four years, 133 scientists were trained in a train-the-trainer programme on advanced tuberculosis culture, drug susceptibility testing, line-probe assays and Xpert(®) MTB/RIF, in addition to safety operations for biosafety facilities. Power instability, running cost and seasonal dust are notable challenges to optimal performance and scale up.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Movable BSL-3 containment laboratories can be deployed to improve diagnostic capacity for drug-resistant tuberculosis and bio-surveillance in settings with limited resources.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aliyu</LastName><ForeName>Gambo</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-9661-3463</Identifier><AffiliationInfo><Affiliation>Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ezati</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute of Human Virology, Abuja, FCT, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwakun</LastName><ForeName>Mosunmola</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Human Virology, Abuja, FCT, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peters</LastName><ForeName>Sam</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Human Virology, Abuja, FCT, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abimiku</LastName><ForeName>Alash'le</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2213-0204</Identifier><AffiliationInfo><Affiliation>Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>03</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>South Africa</Country><MedlineTA>Afr J Lab Med</MedlineTA><NlmUniqueID>101603205</NlmUniqueID><ISSNLinking>2225-2002</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2013 May 09;8(5):e63170</RefSource><PMID Version="1">23671669</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Infect Dis. 2013 Apr;13(4):349-61</RefSource><PMID Version="1">23531388</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Tuberc Res Treat. 2013;2013:650561</RefSource><PMID Version="1">23970967</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Microbiol Rev. 2011 Apr;24(2):314-50</RefSource><PMID Version="1">21482728</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Indian J Med Res. 2014 Aug;140(2):171-83</RefSource><PMID Version="1">25297350</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Microbiol. 2012 Sep;50(9):2905-9</RefSource><PMID Version="1">22740709</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trop Med Int Health. 2011 Aug;16(8):974-80</RefSource><PMID Version="1">21564425</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Health Res Policy Syst. 2015 Jan 15;13:4</RefSource><PMID Version="1">25589057</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Tuberc Lung Dis. 2010 Jan;14(1):59-64</RefSource><PMID Version="1">20003696</PMID></CommentsCorrections></CommentsCorrectionsList><CoiStatement>The interpretation and presentation of the data presented in this report were not influenced by any of the authors’ personal or financial relationships with other people or organisations.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>06</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28879163</ArticleId><ArticleId IdType="doi">10.4102/ajlm.v6i2.502</ArticleId><ArticleId IdType="pii">AJLM-6-502</ArticleId><ArticleId IdType="pmc">PMC5523970</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Nigeria</li><li>États-Unis</li></country><region><li>Maryland</li></region></list><tree><country name="États-Unis"><region name="Maryland"><name sortKey="Aliyu, Gambo" sort="Aliyu, Gambo" uniqKey="Aliyu G" first="Gambo" last="Aliyu">Gambo Aliyu</name></region><name sortKey="Abimiku, Alash Le" sort="Abimiku, Alash Le" uniqKey="Abimiku A" first="Alash'Le" last="Abimiku">Alash'Le Abimiku</name></country><country name="Nigeria"><noRegion><name sortKey="Ezati, Nicholas" sort="Ezati, Nicholas" uniqKey="Ezati N" first="Nicholas" last="Ezati">Nicholas Ezati</name></noRegion><name sortKey="Iwakun, Mosunmola" sort="Iwakun, Mosunmola" uniqKey="Iwakun M" first="Mosunmola" last="Iwakun">Mosunmola Iwakun</name><name sortKey="Peters, Sam" sort="Peters, Sam" uniqKey="Peters S" first="Sam" last="Peters">Sam Peters</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004637 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 004637 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaSubSaharaV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:28879163
|texte= Diagnostic system strengthening for drug resistant tuberculosis in Nigeria: impact and challenges.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:28879163" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a SidaSubSaharaV1
| This area was generated with Dilib version V0.6.32. |  |